Would you offer a RET inhibitor to a patient with de novo metastatic, RET V706M mutant squamous cell lung cancer?

While RET rearrangements certainly provide strong rationale for targeted therapy, is a point mutation such as this considered actionable? Mutation was not present on tissue-based NGS but was detected on liquid-based NGS.